6Wakelee HA, Middleton G, Dunlop D, et al. A phase I pharmacoki- netic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer ( NSCLC ) [ J ]. Cancer Chemother Pharmacol,2012,69(3) :815-824.
7Delord JP,Puozzo C, Lefresne F, et al. Combination chemotherapy of vinorelbine and cisplatin : a phase I pharmacokinetic study in pa- tients with metastatic solid tumors [ J ]. Anticancer Res, 2009,29 (2) :553-560.
8Goss G, Shepherd FA, Laurie S, et al. A phase I and pharmacoki- netic study of daily oral cediranib, an inhibitor of vascular endothe- lial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group[J]. Eur J Cancer,2009,45(5) :782-788.
9Biro K,Noszek L,Prekopp P,et al. Characteristics and risk factors of cisplatin-induced ototoxity in testicular cancer patients detected by distorsion product otoacoustic emission [ J ]. Oncology, 2006,70 (3) :177-184.
10Teranishi M, Nakashima T, Wakabayashi T. Effect of alpha-to- copherol on cisplatin-induced ototoxicity in guinea pigs [ J ]. Hear Res.2001.151 (1/2) :61-70.
